Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:9 Number:33 ISSN#:2563-5476
Author Verified
ACE Report #4488
Ace Report Cover Tumour

Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole

Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10

Contributing Authors: AM Brufsky WG Harker JT Beck L Bosserman C Vogel C Seidler L Jin G Warsi E Argonza-Aviles J Hohneker SG Ericson EA Perez

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Dr. Adam M. Brufsky discusses the use of adjuvant zoledronic acid to maintain bone mass in postmenopausal breast cancer patients.


602 postmenopausal women receiving adjuvant letrozole were randomized either to upfront zoledronic acid or delayed-start zoledronic acid to determine which method minimizes bone-loss. At 5 years follow-up, upfront zoledronic acid was better at maintaining bone mineral density (BMD) in postmenopausal breast cancer patients than the delayed start technique.

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.